Randox Laboratories' Biochip Array Technology has been specifically developed to accelerate the validation of biomarkers in pharmaceutical development and diagnostics.
Following decades of scientific innovation and discovery, it is inconceivable that any new drug would be developed without simultaneously looking at a multitude of biomarkers.
This is because biomarkers are indispensable as: drug efficacy markers; drug toxicity markers; disease predisposition markers; potential targets for new drugs; and the implements of personalised medicine (via pharmacogenomic profiling).
It is widely accepted that the clinical application of validated biomarkers will revolutionise medicine over the coming years.
Already pharmaceuticals are being sold with pharmacogenomic labelling information related to optimising patient selection and personal dosage, but their role in diagnostics will be even more important.
Randox said its key focus is to take any newly discovered biomarkers from the realm of research through to clinical utility, whether in the pharmaceutical industry and clinical trials or the wider healthcare industry.
However, the process to successfully validate a biomarker is often just as lengthy and costly as for a drug candidate and key to this process is to provide accurate clinical trial results.
Randox's Biochip Array Technology is said to offer 'diagnostic grade' results and the in-built accuracy, precision and specificity of the platform will assist in study publications, clinical trial results and ultimately biomarker validation.
Randox Laboratories offers a range of biochip analysers and a selection of biomarker arrays.
